Simulations Plus to Acquire DILIsym Services, Inc. This acquisition seems to be a perfect fit for the Simulations Plus business model. DILIsym Services, Inc. (“DILIsym Services”) will become a wholly owned subsidiary of Simulations Plus, Inc. (“Simulations Plus”) and will continue to operate under the DILIsym Services name. This accretive acquisition will result in the total number of Simulations Plus employees increasing from 68 to 79, and is expected to add more than $3 million to the revenues of the combined company in the coming fiscal year 2018. Simulations Plus will pay the shareholders of DILIsym Services cash consideration of up to $10 million, comprised of $5 million up front plus an earn-out of up to an additional $5 million over the next three years, based on the profitability of the DILIsym Services division. The Agreement provides that $1 million of the total up-front consideration will be held back for 18 months to satisfy any indemnifiable claims that may arise pursuant to the terms of the Agreement. For calendar year 2016, its most recent fiscal year, DILIsym Services, Inc. revenues were just over $3 million with net earnings of approximately $720,000. More information is available on the company’s Web site at https://www.dilisym.com. The complete release is at the link: https://www.sec.gov/Archives/edgar/data/1023459/000168316817001055/simulations_8k-ex9901.htm This is another example of how the SLP management team is doing an excellent job of using resources wisely and to the advantage of the stockholders. SLP stock is valued at approximately 10 X sales and they are buying a company for about 3 X sales. And the acquisition is immediately accretive resulting in about 4-5 cents per share increase in SLP earnings. Another job well done. Thanks to the hard working team at Simulations Plus. I am happy to be a shareholder.
Täglich has a new research report update on SLP. Keep in mind this update was made before the acquisition was announced today.
Key Investment Considerations: Maintaining Buy rating and increasing our 12-month price target to $13.35 per share from $12.30 due to increased sector and SLP’s valuations, partly restrained by a minimal reduction in our FY18 forecast. SLP’s long-term growth should be driven by the use of software tools and analytics for drug discovery and development increases, expansion of the acquired Cognigen Corp. business, and development of new solutions for clients’ research and development programs. In April 2016 a $4.7 million, five-year contract was signed by a major research foundation for Cognigen’s KIWI cloud-based software collaboration platform. The platform will be used for the foundation’s global teams engaged in model based drug development. SLP has penetrated nearly 20% of the pharmaceutical, biotechnology, and generic companies that would be potential users of its software and/or consulting services. In April 2017, an agreement with Quantum Bio Solutions of Korea gave SLP the opportunity to sell its software tools to at least 40 new organizations in Korea. 2Q17 EPS (reported 4/10/17) was flat at $0.07, on a 10.5% rise in sales to $5.7 million. We forecasted sales of $5.5 million and EPS of $0.08. Our FY17 sales and income forecasts are largely unchanged at $22 million and $2.6 million or $0.31 per share. For FY18, we reduced by $0.01 per share our EPS projection to $0.36 on sales growth of 10% to $24.2 million (prior was $24.5 million) due primarily to new customer growth falling short of our prior forecast (125 vs. 150 in January 2017). The decrease in our customer forecast reflects a slower than anticipated ramp of the company’s PKPlusTM software offering (launched in 4Q16), partly offset by growth in consulting services. Maintaining Buy rating due to SLP’s growth potential, which should be sustained due to the increasing use of software tools and analytics for drug discovery and development, and leveraging the acquisition of Cognigen Corp. The collaboration between Cognigen and SLP scientists has resulted in new and innovative solutions for its clients’ research and development programs. The acquisition and growing client base should underlie accelerating net income growth in FY18. Full report is available at: http://www.taglichbrothers.com/companyreports/simplus/simplus-04242017.pdf
SLP hit a new high yesterday, will it hold this time? Been here for ten years, a long-term investment in a solid company. Regards to Mr. Milde.
Classic drop near 12 dollar level. Shish. Too many profit takers. I believe SLP's endeavors to sale in S. Korea and India will bode well.
http://monstastocks.com/?s=SLP has an alert for $SLP. Did anyone happen to see it as well? Looking for some good positive information from the company! Day trading investing. After all
Monsta Stocks: Trading Stocks and Making Money
Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.
Simulations Plus Finalizes Distributor Agreement With Korean Company Simulations Plus, Inc. (SLP), a leading provider of modeling & simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has entered into a distributor agreement in South Korea with Quantum Bio Solutions (Q-Bio).
John DiBella, vice president for marketing and sales of Simulations Plus, said: “We are excited to be partnering with Q-Bio to further serve the needs of the South Korean scientific markets. We have been hosting annual GastroPlus™ modeling & simulation workshops at Chungnam National University in Daejeon, South Korea since 2014, and we have been encouraged by the response to our technology. The South Korean government has pledged nearly $9 billion to help domestic drug makers develop twenty new drugs with the goal of being among the world’s top seven global pharmaceutical producing countries by the year 2020. Therefore, we see this as a most opportune time to have a local presence in South Korea to increase awareness of Simulations Plus and our suite of offerings, while also strengthening the relationships we have already formed with South Korean companies and universities.” https://finance.yahoo.com/news/simulations-plus-finalizes-distributor-agreement-123000368.html You can be sure that SLP would not be setting up a distributor unless they had expectations of additional sales.
Simulations Plus Finalizes Distributor Agreement With Korean Company
Simulations Plus, Inc. , a leading provider of modeling & simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has entered into a distributor agreement in South Korea with Quantum Bio Solutions
SLP just can't get over the hump. As soon as it approaches 12 or high 11's, there is a sell off.This has been going on for over 2 years. I agree with #$%$ that this company is steady and growing.I wonder what it will ever take for it to have a higher projectory? SLP is a good place to parkmoney and be relatively safe unless another large company creates a better mouse-trap.
47% of the days in March were above average volume and the stock is up over 14% for the month. So it's reasonable to assume that someone is taking a page position. They will be pleased with their investment. I have been a share holder for many years and have never been disappointed. Although the price of the stock has considerably volatility the management of SLP has been rock solid. There has never been a decision that has not been in the best interest of stock holders.
SLP's recent run -
Might just be end of calendar quarter buying for show (hopefully not) so may see a dip on Monday, but regardless its value remains high.
New 52 week high on 3X volume :-)
Simulations Plus Reports Record Preliminary Revenues for Second Quarter FY2017 Preliminary revenues for the three months ended February 28, 2017, were $5.64 million, compared to $5.16 million for the same period in 2016. This represents an increase of 9.3%, or $480,000. Preliminary revenues for the six months ended February 28, 2017, were $11.06 million, compared to $10.00 million for the same period in 2016. This represents an increase of 10.6%, or $1.06 million. Approximately 68% of 2QFY17 revenues were from software and software-related training services. Software and software-related services were up approximately 8.0% for 2QFY17 compared to 2QFY16. Software and software-related services were up approximately 8.0% for 2QFY17 compared to 2QFY16. Approximately 32% of 2QFY17 revenues were from consulting services and analytical studies including collaborations. Lancaster analytical study and collaboration revenues were approximately $260,000 for 2QFY17, an increase of $110,000 when compared to 2QFY16. Buffalo revenues increased by 6.1%, or $90,000, to $1.57 million from $1.48 million for 2QFY17 compared to 2QFY16. Lancaster analytical study and collaboration revenues were approximately $260,000 for 2QFY17, an increase of $110,000 when compared to 2QFY16. Buffalo revenues increased by 6.1%, or $90,000, to $1.57 million from $1.48 million for 2QFY17 compared to 2QFY16. During 2QFY17, the company added 20 new software customers, for a total of 43 for the six months ended February 28, 2017. Cash as of February 28, 2017, was $7.4 million after the Company made a dividend distribution of approximately $862,000 on February 6, 2017 "Finally, our aggressive global training workshop and conference schedule will assist us with our goal of educating more scientists and promoting our modeling & simulation solutions to different audiences, and we anticipate these activities will help our longstanding positive momentum in revenue growth to continue.” https://finance.yahoo.com/news/simulations-plus-reports-record-preliminary-123000054.html
Rocket Ship Ready !
My theory is that the longer we keep hitting that $10.10 ceiling the closer we are to higher prices :-)
So- why the big surge in volume today?
Taglich provides their analyst update... Key Investment Considerations: Maintaining Buy rating and increasing our 12-month price target to $12.30 per share from $11.95 due to increased sector and SLP’s valuations. SLP’s long-term growth should be driven by the use of software tools and analytics for drug discovery and development increases, expansion of the acquired Cognigen Corp. business, and development of new solutions for clients’ research and development programs. In April 2016 SLP received a $4.7 million, five-year contract from a major research foundation for Cognigen’s KIWI’s cloud-based software collaboration platform, which will be used for the foundation’s global teams engaged in model based drug development. The biosimulation (model-based prediction) technology market is projected to grow 16.6% annually, reaching $3 billion in 2022. SLP has penetrated approximately 20% of the viable pharmaceutical, biotechnology, and generic companies that would be potential users of the company’s software and/or consulting services. 1Q17 EPS (reported 1/9/17) increased $0.02 per share to $0.08, on a 12% rise in sales to $5.4 million. We forecasted sales of $5 million and EPS of $0.07. Our FY17 sales and income forecasts are largely unchanged at $22 million and $2.6 million or $0.32 per share. For FY18, we maintained our EPS projection of $0.37 per share on sales growth of 11.3% to $24.5 million due primarily to anticipated new customer growth to 150, up from 125 in FY17 and 75 in FY16. The PKPlusTM software offering (launch in 4Q16) and demand for its consulting services should support SLP’s sales growth. The full report is available at:http://www.taglichbrothers.com/companyreports/simplus/simplus-01132017.pdf
For you technicians, the 1 yr chart is a thing of beauty. I tend not to read too much into charts for lightly traded small caps, but a nice cup and handle forming. If we get some volume and momentum in the market in general, this thing could move up in a hurry.
There seems to be a concrete wall at $10.10.. I don't know why.. The last quarter and guidance should have resulted in a higher share price..
SLP reports another record quarter ! 1QFY17 highlights compared with 1QFY16:
Net revenues increased 12.0%, or $579,000, to a new first quarter record $5.42 million vs. $4.84 million Gross profit increased 8.7% to $4.08 million from $3.76 million SG&A was $1.86 million, an increase of $187,000 or 11.2%, from $1.68 million SG&A as a percentage of revenues decreased slightly from 34.6% to 34.4% Income before taxes increased $250,000 or 14.6%, to $1.97 million from $1.72 million Net income increased $255,000 or 23.1%, to $1.36 million from $1.11 million Diluted earnings per share increased 22% or $0.014, to $0.078 from $0.064 per share
Look at todays chart- can you say "market manipulation"? (Not by the company- buy a MM.
What caused the large drop in price today at about 3:30? Anyone have any idea?